86 related articles for article (PubMed ID: 17389868)
21. Cost-effectiveness analyses of health promotion programs: a case study of smoking prevention and cessation among Dutch students.
Vijgen SM; van Baal PH; Hoogenveen RT; de Wit GA; Feenstra TL
Health Educ Res; 2008 Apr; 23(2):310-8. PubMed ID: 17675649
[TBL] [Abstract][Full Text] [Related]
22. Rotavirus vaccination for Hong Kong children: an economic evaluation from the Hong Kong Government perspective.
Ho AM; Nelson EA; Walker DG
Arch Dis Child; 2008 Jan; 93(1):52-8. PubMed ID: 17855438
[TBL] [Abstract][Full Text] [Related]
23. Comments on the Prosser et Al approach to value disease reduction in children.
Beutels P; Viney RC
Pediatrics; 2004 Nov; 114(5):1375; author reply 1375-6. PubMed ID: 15520142
[No Abstract] [Full Text] [Related]
24. Technology assessment in the German context.
Drummond M
Eur J Health Econ; 2007 Sep; 8 Suppl 1():S3. PubMed ID: 17619919
[No Abstract] [Full Text] [Related]
25. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
[TBL] [Abstract][Full Text] [Related]
26. Using costs in cost-effectiveness models for chronic diseases: lessons from diabetes.
Hoerger TJ
Med Care; 2009 Jul; 47(7 Suppl 1):S21-7. PubMed ID: 19536014
[TBL] [Abstract][Full Text] [Related]
27. Financial impact of obesity and bariatric surgery.
Powers KA; Rehrig ST; Jones DB
Med Clin North Am; 2007 May; 91(3):321-38, ix. PubMed ID: 17509381
[TBL] [Abstract][Full Text] [Related]
28. Economic evaluation of the US Environmental Protection Agency's SunWise program: sun protection education for young children.
Kyle JW; Hammitt JK; Lim HW; Geller AC; Hall-Jordan LH; Maibach EW; De Fabo EC; Wagner MC
Pediatrics; 2008 May; 121(5):e1074-84. PubMed ID: 18450850
[TBL] [Abstract][Full Text] [Related]
29. Health utility and economic analysis: theoretical and practical issues.
Payakachat N; Murawski MM; Summers KH
Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):289-92. PubMed ID: 19670986
[No Abstract] [Full Text] [Related]
30. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
[TBL] [Abstract][Full Text] [Related]
31. Welfare economics and cost-utility analysis.
Butler JR
Dev Health Econ Public Policy; 1992; 1():143-57. PubMed ID: 10151743
[No Abstract] [Full Text] [Related]
32. Cost-effectiveness of influenza vaccination in working-age cancer patients.
Avritscher EB; Cooksley CD; Geraci JM; Bekele BN; Cantor SB; Rolston KV; Elting LS
Cancer; 2007 Jun; 109(11):2357-64. PubMed ID: 17457827
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis and innovation.
Jena AB; Philipson TJ
J Health Econ; 2008 Sep; 27(5):1224-36. PubMed ID: 18619695
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis of endometrial cancer prevention strategies for obese women.
Kwon JS; Lu KH
Obstet Gynecol; 2008 Jul; 112(1):56-63. PubMed ID: 18591308
[TBL] [Abstract][Full Text] [Related]
35. The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.
Aballéa S; De Juanes JR; Barbieri M; Martin M; Chancellor J; Oyagüez I; Verwee B; Largeron N
Vaccine; 2007 Sep; 25(39-40):6900-10. PubMed ID: 17764790
[TBL] [Abstract][Full Text] [Related]
36. Health-related quality of life after stroke: review of the literature and implications for future research.
Tseng MC; Lin HJ
Acta Neurol Taiwan; 2007 Mar; 16(1):7-12. PubMed ID: 17486727
[TBL] [Abstract][Full Text] [Related]
37. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of alternative first-trimester pregnancy termination strategies in Mexico City.
Hu D; Grossman D; Levin C; Blanchard K; Goldie SJ
BJOG; 2009 May; 116(6):768-79. PubMed ID: 19432565
[TBL] [Abstract][Full Text] [Related]
39. An evidence-based model comparing the cost-effectiveness of platelet-rich plasma gel to alternative therapies for patients with nonhealing diabetic foot ulcers.
Dougherty EJ
Adv Skin Wound Care; 2008 Dec; 21(12):568-75. PubMed ID: 19065083
[TBL] [Abstract][Full Text] [Related]
40. Valuing reduced antibiotic use for pediatric acute otitis media.
Meropol SB
Pediatrics; 2008 Apr; 121(4):669-73. PubMed ID: 18381529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
